Kathleen Adams is a healthcare and life sciences executive with extensive experience in marketing, new product development, and commercialization; her accomplishments have contributed to organizations ranging from Fortune 100 pharma companies and venture-backed diagnostics start-ups to a globally recognized academic research institution. Kate has a Bachelor’s in Biology and Philosophy from Bryn Mawr College and an MBA from the Yale School of Management. She was Product Manager for Intron A at Schering-Plough; Associate Director of New Business Development at Parke-Davis; Director of Oncology & Specialty Physician Marketing at Quest Diagnostics; served on the Board of Directors of Enterix, a privately held small diagnostics manufacturer; was VP of Marketing at HistoRx, a venture-backed start-up diagnostic firm sold to a Novartis subsidiary; and Program Director of Clinical Innovation at The Jackson Laboratory for Genomic Medicine. Kate is now advising start-up companies as an Entrepreneur-in-Residence at UCONN’s Technology Incubation Program, and independently as a consultant.
Kathleen Q. Adams MBA, Chief Commercial Officer
Brian Ciarcia, IT Director
Brian is a 25+ year expert in cloud architecture with prior experience spanning from the US Military to the Healthcare Industry. He maintains a broad expertise in multiple software operating environments, with a special focus on security and compliance. In his career he has successfully reduced IT budgets by over 35%, increased the overall security footprint by 75%, and drastically increased staff efficiency in today's mobile workforce. Brian is Director of Information Technology for SoNE Health since 2021. Prior to that he was a partner at Aegis Information Systems (Rocky Hill, CT) managing network infrastructures for various industries, including non-profit, law firms and hospitals (2020-2021). Before that he served as IT Manager at Pepe & Hazard LLP, handling litigation support, cloud computing and document management (2000-2010). Prior to that he served a 4-year active duty in the U.S. Air Force, where he maintained a Top-Secret Clearance monitoring communications for the armed forces. Before that he served a 4-year Active Duty in the U.S. Army where he specialized in installation of military base fiber networks, as well as managing computer fleets.
Kenneth I Kaitin PhD, Director
Kenneth Kaitin is a Professor at Tufts University School of Medicine and Senior Fellow at Tufts Center for the Study of Drug Development. He is also Advisory Professor at Shanghai Medical College at Fudan University and serves on the faculty of the European Center for Pharmaceutical Medicine at the University of Basel. Dr. Kaitin is internationally recognized for contributions to the fields of drug development policy and science. He consults, speaks, and writes on global trends in pharmaceutical development, and he has provided public testimony before the U.S. Congress. A former President of the Drug Information Association, Dr. Kaitin recently served as Editor-in-Chief of Expert Review of Clinical Pharmacology, and as a consultant to the U.S. Department of Defense on bioterror countermeasures. In 2011, he received the Dr. Louis M. Sherwood Award, granted by the Academy of Pharmaceutical Physicians and Investigators; in 2020 he was named Global Fellow in Medicines Development by the International Federation of Pharmaceutical Physicians, and in 2021 he received the Distinguished Achievement Award from the Sino-American Pharmaceutical Professionals Association (SAPA). Dr. Kaitin is a director on the boards of Curis, Inc. (NASDAQ: CRIS), Bio-Tree Systems, Inc., and QCDx. He earned his BS from Cornell University and MS and PhD in pharmacology from the University of Rochester
Fahmy has 10+ years of professional experience in academia, clinical, and industrial settings. In addition to his expertise in oncology medical communications, Dr. Mamuya has a strong background in high-end research imaging gained from his biomedical research studies and his roles as a research imaging specialist within the microscopy industry. He received a Ph.D. in Cells, Organs, and System Physiology from the University of Delaware. He studied epithelial cell behavior after injury/surgery and showed excellent potential for secondary cataract therapeutics that are currently under development. Dr. Mamuya continued his academic research career as a Post-Doctoral Fellow at Massachusetts General Hospital and Harvard Medical School and published his work on integrin receptors' critical roles in kidney development and function. He holds an MBA from the University of Delaware and is Adjunct Professor at Bay Path University Master's program in Applied Laboratory Science & Operations.
Fahmy A Mamuya PhD, MBA, Lead Scientist
Harry H Penner JD LLM, Co-Founder & Director
Harry has 30+ years of executive experience in the pharmaceutical and biotechnology sectors. He is currently on the Board of Directors of Prevention Pharmaceuticals, Affinimark Technologies, Neurovail, Aria Neurosciences, and Carogen. He has been a director of Celldex since the merger between Celldex and AVANT Immunotherapeutics in March 2008 and had been a director of AVANT since 1997. In 2001, he founded Nascent BioScience, a firm engaged in the creation and development of new biotechnology companies, where he is currently Chairman and Chief Executive Officer. From 1993 to 2001, he was President, Chief Executive Officer, and Vice Chairman of Neurogen Corporation. From 1985 to 1993, he was an Executive Vice President of Novo Nordisk A/S, serving from 1988 to 1993 as Executive Vice President for North America and President, Novo Nordisk of North America. From 1985 to 1988 he was the company's Executive Vice President and General Counsel in Denmark. He has served as BioScience Advisor to the Governor and the State of Connecticut, Co-Chair of Connecticut United for Research Excellence, Chair of the Connecticut Board of Governors of Higher Education, and Chair of the Connecticut Technology Council. Mr. Penner received a B.A. from the University of Virginia, a J.D. from Fordham University, and an L.L.M. in International Law from New York University
Liming Shao PhD, Advisor to the Board
Liming is a Professor of Medicinal Chemistry at School of Pharmacy, Fudan University, Shanghai, and Director of the Shanghai Center for Drug Discovery & Development. Prior to joining Fudan University, Liming was a senior director at Sepracor Inc./Sunovion Pharmaceuticals Inc. in drug discovery research. For over 30 years, as a medicinal chemist, Liming participated in or led programs that cover a broad range of drug discovery research and development and which have resulted in 20 advanced leads for preclinical development for the treatment of pain, depression, ADHA, schizophrenia, Parkinson’s disease and the acceptance by the FDA of 4 IND applications and 1 NDA. Liming’s academic training was at the Tokyo University where he received his Ph.D. in Organic Chemistry followed by a postdoctoral fellowship at Harvard University.
Triantafyllos (Fyl) Tafas PhD, Founder, CEO & Director
Fyl is a Life Sciences entrepreneur and developer of precision diagnostics aiming to transform human health. He founded QCDx in 2017 to develop and commercialize a next-generation rare cell detection technology, by leading a multi-disciplinary team, working at the intersection of genomics, optics, microfluidics, and big data. He co-founded Ikonisys Inc. in 2000 and served as the CSO, CTO and then President a robotic microscopy platform and diagnostic products used by major clinical customers in the US and Europe to deliver more than 300,000 cancer diagnostic tests. Prior to that, he developed a new prenatal Down screening biomarker which was licensed to Chromavision (Clarient Inc. /Neogenomics) and introduced the first Prenatal Chromosomal Abnormalities Screening Program for Greece. He co-authored more than seventy publications and is the co-inventor to 38 US patents and multiple patents pending. He was awarded the prestigious Jefferson Medal Award by the New Jersey Intellectual Property Law Association and the Distinguished Services Award from the University of Athens, Greece. He is holding a B.S. in biology and Ph.D. in ecology and populations biology from the University of Athens.
Andreas Typaldos, Director
Mr. Typaldos is a veteran and pioneer software and technology entrepreneur, as well as founder and/or owner of businesses in the hospitality and other commercial areas. He has been founder and founding or early investor of a number of software and technology companies in the US and Europe through a Typaldos Family Office. He has deep and broad management and enterprise development experience, with expertise and international and financial contacts, over a wide range of industries. He is CEO of Xandros Inc. He co-founded Cogia GMBH (Frankfurt, DE). He is the major shareholder of CoinAnalyst. He is Executive Chairman of Bridgeways Inc and Chairman of Arkados Group Inc. He is the founder, CEO, and venture partner of the Kerna Group, and Chairman or CEO of a number of Group companies. He is Chairman and CEO of Scalix Corporation. He is holding a BS in Mathematical Methods for Engineering and Operations from Columbia University and a Masters in Computer Science from Pratt Institute.
Paul C White, Director
Paul White has 25+ years as a senior executive with diverse industry experience including healthcare, media and high tech. Mr. White currently runs a boutique consulting firm focused on driving profitable growth, where he serves as a senior advisor to PE firms and private companies.
Paul began his career as a CPA and business consultant for two “big six” firms (now Accenture and EY), and then began a journey as a “serial CFO and business leader”. From 2020 to 2021 he was the CFO of Hunter Quinn Homes, where he positioned the company for 3-4X growth. From 2014 to 2019 he served as SVP of Business Transformation for Outfront Media, a $2B public advertising company where his efforts created $100M+ in recurring, bottom-line profits. From 2012 to 2014 he served as VP in charge of the video business of Frontier Communications, a $200B telecom, where he grew that unit by 3X. From 2010 to 2012 he was CFO of EJ Electric, the largest Electrical Contractor in NYC, where he helped grow the company by 260%. From 2006 to 2010 he served as first CFO and then President of Ikonisys, helping to transition from pre-revenue to revenue producing and raising $50M+ along the way. From 2000 to 2006 he served as CFO of Deltathree, a public VOIP Pioneer which he helped drive to a profitable, white-label provider to the largest telecoms. Mr. White earned both his BBA and MBA a Hofstra University.